382 related articles for article (PubMed ID: 25560784)
1. Establishing prostate cancer patient derived xenografts: lessons learned from older studies.
Russell PJ; Russell P; Rudduck C; Tse BW; Williams ED; Raghavan D
Prostate; 2015 May; 75(6):628-36. PubMed ID: 25560784
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
3. Development of seven new human prostate tumor xenograft models and their histopathological characterization.
van Weerden WM; de Ridder CM; Verdaasdonk CL; Romijn JC; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Am J Pathol; 1996 Sep; 149(3):1055-62. PubMed ID: 8780407
[TBL] [Abstract][Full Text] [Related]
4. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
5. Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.
Lawrence MG; Pook DW; Wang H; Porter LH; Frydenberg M; Kourambas J; Appu S; Poole C; Beardsley EK; Ryan A; Norden S; Papargiris MM; Risbridger GP; Taylor RA
Prostate; 2015 Sep; 75(13):1475-83. PubMed ID: 26177841
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Ellis WJ; Vessella RL; Buhler KR; Bladou F; True LD; Bigler SA; Curtis D; Lange PH
Clin Cancer Res; 1996 Jun; 2(6):1039-48. PubMed ID: 9816265
[TBL] [Abstract][Full Text] [Related]
7. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
[TBL] [Abstract][Full Text] [Related]
8. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
9. The prostatic environment suppresses growth of androgen-independent prostate cancer xenografts: an effect influenced by testosterone.
Jennbacken K; Gustavsson H; Tesan T; Horn M; Vallbo C; Welén K; Damber JE
Prostate; 2009 Aug; 69(11):1164-75. PubMed ID: 19399749
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer xenografts: a model of tumor cell heterogeneity.
Russell PJ; Raghavan D; Gregory P; Philips J; Wills EJ; Jelbart M; Wass J; Zbroja RA; Vincent PC
Cancer Res; 1986 Apr; 46(4 Pt 2):2035-40. PubMed ID: 2418959
[TBL] [Abstract][Full Text] [Related]
11. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.
Wetterauer C; Vlajnic T; Schüler J; Gsponer JR; Thalmann GN; Cecchini M; Schneider J; Zellweger T; Pueschel H; Bachmann A; Ruiz C; Dirnhofer S; Bubendorf L; Rentsch CA
Prostate; 2015 May; 75(6):585-92. PubMed ID: 25585936
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of a new human prostatic cancer cell line: DuCaP.
Lee YG; Korenchuk S; Lehr J; Whitney S; Vessela R; Pienta KJ
In Vivo; 2001; 15(2):157-62. PubMed ID: 11317521
[TBL] [Abstract][Full Text] [Related]
13. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
[TBL] [Abstract][Full Text] [Related]
14. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
Chauchereau A; Al Nakouzi N; Gaudin C; Le Moulec S; Compagno D; Auger N; Bénard J; Opolon P; Rozet F; Validire P; Fromont G; Fizazi K
Exp Cell Res; 2011 Feb; 317(3):262-75. PubMed ID: 20974126
[TBL] [Abstract][Full Text] [Related]
15. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
[TBL] [Abstract][Full Text] [Related]
16. VCaP, a cell-based model system of human prostate cancer.
Korenchuk S; Lehr JE; MClean L; Lee YG; Whitney S; Vessella R; Lin DL; Pienta KJ
In Vivo; 2001; 15(2):163-8. PubMed ID: 11317522
[TBL] [Abstract][Full Text] [Related]
17. BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis.
McCulloch DR; Opeskin K; Thompson EW; Williams ED
Prostate; 2005 Sep; 65(1):35-43. PubMed ID: 15800936
[TBL] [Abstract][Full Text] [Related]
18. Xenografts of primary human prostatic carcinoma.
Pretlow TG; Wolman SR; Micale MA; Pelley RJ; Kursh ED; Resnick MI; Bodner DR; Jacobberger JW; Delmoro CM; Giaconia JM
J Natl Cancer Inst; 1993 Mar; 85(5):394-8. PubMed ID: 8433392
[TBL] [Abstract][Full Text] [Related]
19. An original patient-derived xenograft of prostate cancer with cyst formation.
Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
[TBL] [Abstract][Full Text] [Related]
20. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.
Cutz JC; Guan J; Bayani J; Yoshimoto M; Xue H; Sutcliffe M; English J; Flint J; LeRiche J; Yee J; Squire JA; Gout PW; Lam S; Wang YZ
Clin Cancer Res; 2006 Jul; 12(13):4043-54. PubMed ID: 16818704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]